Market open
Kura Oncology/$KURA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kura Oncology
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
Ticker
$KURA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
192
Website
Kura Oncology Metrics
BasicAdvanced
$498M
-
-$2.02
0.84
-
Price and volume
Market cap
$498M
Beta
0.84
52-week high
$23.48
52-week low
$5.99
Average daily volume
1.2M
Financial strength
Current ratio
9.463
Quick ratio
9.319
Long term debt to equity
2.927
Total debt to equity
4.012
Interest coverage (TTM)
-119.33%
Management effectiveness
Return on assets (TTM)
-19.97%
Return on equity (TTM)
-42.91%
Valuation
Price to revenue (TTM)
9.866
Price to book
1.13
Price to tangible book (TTM)
1.13
Price to free cash flow (TTM)
3.972
Growth
Earnings per share change (TTM)
-3.12%
3-year earnings per share growth (CAGR)
0.89%
What the Analysts think about Kura Oncology
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Kura Oncology stock.
Kura Oncology Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Kura Oncology Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Kura Oncology News
AllArticlesVideos
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·7 hours ago
Kura Oncology to Participate in Stifel Targeted Oncology Forum
GlobeNewsWire·3 days ago
Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Kura Oncology stock?
Kura Oncology (KURA) has a market cap of $498M as of April 04, 2025.
What is the P/E ratio for Kura Oncology stock?
The price to earnings (P/E) ratio for Kura Oncology (KURA) stock is 0 as of April 04, 2025.
Does Kura Oncology stock pay dividends?
No, Kura Oncology (KURA) stock does not pay dividends to its shareholders as of April 04, 2025.
When is the next Kura Oncology dividend payment date?
Kura Oncology (KURA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kura Oncology?
Kura Oncology (KURA) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.